Nanotechnology-based drug delivery systems

Journal of Occupational Medicine and Toxicology

Volumn 2, Issue 1, 2007, Pages

  Suri, Sarabjeet Singh ^a   Fenniri, Hicham ^b   Singh, Baljit ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38849149655     PISSN: None     EISSN: 17456673     Source Type: Journal    
DOI: 10.1186/1745-6673-2-16     Document Type: Article

References (49)

1. Nanomedicine for respiratory diseases. U Pison T Welte M Giersing DA Groneberg, Eu J Pharmacology 2006 533 341 350 10.1016/j.ejphar.2005.12.068
2. Nanoparticle and targeted systems for cancer therapy. L Brannon-Peppase JQ Blanchette, Adv Drug Deliv Rev 2004 56 11 1649 1659 10.1016/j.addr.2004.02. 014 15350294
3. Applications of nanotechnologies in medical practice. GK Stylios PV Giannoudis T Wan, Injury 2005 36 S6 S13 10.1016/j.injury.2005.10.011 16291325
4. Drug targeting with nano-sized carrier systems. M Yokoyama, J Artif Organs 2005 8 2 77 84 10.1007/s10047-005-0285-0 16094510
5. Delivering cancer stem cell therapies - a role for nanomedicines? AG Schatzlein, Eur J Cancer 2006 42 9 1309 1315 10.1016/j.ejca.2006.01.044 16682183
6. Novel concepts of neuropeptide-based therapy: Vasoactive intestinal polypeptide and its receptors. DA Groneberg KF rabe A Fischer, Eu J Pharmacology 2006 533 182 194 10.1016/j.ejphar.2005.12.055
7. Epigenetic events in the colorectum and in colon cancer. WM Grady, Biochem Soc Trans 2005 33 684 688 10.1042/BST0330684 16042574
8. Self-assembling PEG-p(CL-co-TMC) copolymers for oral delivery of poorly water-soluble drugs: a case study with risperidone. L Ould-Ouali M Noppe X Langlois B Willems P Te Riele P Timmerman ME Brewster A Arien V Preat, J Control Release 2005 102 3 657 668 10.1016/j.jconrel.2004.10.022 15681087
9. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. JE Kipp, Int J Pharm 2004 284 1-2 109 122 10.1016/j.ijpharm.2004.07.019 15454302
10. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. C Fonseca S Simoes R Gaspar, J Control Release 2002 83 2 273 286 10.1016/S0168-3659(02)00212-2 12363453
11. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. JM Koziara TR Whisman MT Tseng RJ Mumper, J Control Release 2006 112 3 312 319 10.1016/j.jconrel.2006.03.001 16626835
12. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. HS Yoo KH Lee JE Oh TG Park, J Control Release 2000 68 3 419 31 10.1016/S0168-3659(00)00280-7 10974396
13. A PEGylated dendritic nanoparticulate carrier of fluorouracil. D Bhadra S Bhadra S Jain NK Jain, Int J Pharm 2003 257 1-2 111 124 10.1016/S0378-5173(03) 00132-7 12711167
14. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. J Panyam V Labhasetwar, Mol Pharm 2004 1 1 77 84 10.1021/mp034002c 15832503
15. Paclitaxel nanoparticles for the potential treatment of brain tumors. JM Koziara PR Lockman DD Allen RJ Mumper, J Control Release 2004 99 2 259 269 10.1016/j.jconrel.2004.07.006 15380635
16. Quantum dots to monitor RNAi delivery and improve gene silencing. AA Chen AM Derfus SR Khetani SN Bhatia, Nucleic Acids Res 2005 33 22 e190 16352864 10.1093/nar/gni188
17. PEG-PLA/PLGA Nanoparticles for In-Vivo RNAi Delivery. RR Shinde MH Bachmann Q Wang R Kasper CH Contag, NSTI Nano tech., California 2007
18. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. WB Tan S Jiang Y Zhang, Biomaterials 2007 28 8 1565 1571 10.1016/j.biomaterials.2006.11.018 17161865
19. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. KA Howard UL Rahbek X Liu CK Damgaard SZ Glud M Andersen MB Hovgaard A Schmitz JR Nyengaard F Besenbacher J Kjems, Mol Ther 2006 14 4 476 484 10.1016/j.ymthe.2006.04.010 16829204
20. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Kreuter D Shamenkov V Petrov P Ramge K Cychutek C Koch-Brandt R Alyautdin, J Drug Target 2002 10 4 317 325 10.1080/ 10611860290031877 12164380
21. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. L Costantino F Gandolfi G Tosi F Rivasi MA Vandelli F Forni, J Control Release 2005 108 1 84 96 10.1016/j.jconrel.2005.07.013 16154222
22. Alexa Fluor 488 as an iron sensing molecule and its application in PEBBLE nanosensors. JP Sumner R Kopelman, Analyst 2005 130 4 528 533 10.1039/b414189j 15776163
23. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. K Michaelis MM Hoffmann S Dreis E Herbert RN Alyautdin M Michaelis J Kreuter K Langer, J Pharmacol Exp Ther 2006 317 3 1246 1253 10.1124/jpet.105.097139 16554356
24. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. SC Steiniger J Kreuter AS Khalansky IN Skidan AI Bobruskin ZS Smirnova SE Severin R Uhl M Kock KD Geiger SE Gelperina, Int J Cancer 2004 109 5 759 767 10.1002/ijc.20048 14999786
25. Self-Assembled Coatings on Individual Monodisperse Magnetite Nanoparticles for Efficient Intracellular Uptake. Y Zhang C Sun N Kohler M Zhang, Biomedical Microdevices 2004 6 33 40 10.1023/B:BMMD.0000013363.77466.63 15307442
26. A Novel Antiangiogenesis Therapy Using an Integrin Antagonist or Anti-Flk-1 Antibody Coated 90Y-labeled Nanoparticles. L Li CA Wartchow SN Danthi Z Shen N Dechene J Pease HS Choi T Doede P Chu S Ning DY Lee MD Bednarski SJ Knox, Int J Radiat Oncol Biol Phy 2004 58 4 1215 1227
27. Self-assembled nanoparticles based on glycol chitosan bearing 5beta-cholanic acid for RGD peptide delivery. JH Park S Kwon JO Nam RW Park H Chung SB Seo IS Kim IC Kwon SY Jeong, J Control Release 2004 95 3 579 588 10.1016/j.jconrel.2003.12.020 15023468
28. Entropically driven self-assembly of multichannel rosette nanotubes. H Fenniri BL Deng AE Ribbe K Hallenga J Jacob P Thiyagarajan, Proc Nat Acad Sci 2002 99 6487 6492 11891281 10.1073/pnas.032527099
29. Helical rosette nanotubes: design, self-assembly, and characterization. H Fenniri P Mathivanan KL Vidale DM Sherman K Hallenga KV Wood JG Stowell, J Am Chem Soc 2001 123 3854 3855 10.1021/ja005886l 11457132
30. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. D Zhang T Tan L Gao W Zhao P Wang, Drug Dev Ind Pharm 2007 33 5 569 575 10.1080/ 03639040600975147 17520449
31. Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular leishmania donovani associated with hydrogen peroxide production. R Gaspar V Préat FR Opperdoes M Roland, Pharmaceutical Research 1992 9 6 782 787 10.1023/A:1015807706530 1409361
32. Intracellular distribution of ampiciUin in murine macrophages infected with Salmonella typhimurium and treated with (3H)ampicillin-loaded nanoparticles. O Balland H Pinto-Alphandary A Viron E Puvion A Andremont P Couvreur, Journal of Antimicrobial Chemotherapy 1996 37 105 115 10.1093/jac/37.1.105 8647751
33. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. S Gupta SP Viyas, J Drug Target 2007 15 3 206 217 10.1080/10611860701195395 17454358
34. A reevaluation of integrins as regulators of angiogenesis. RO Hynes, Nat Med 2002 8 918 921 10.1038/nm0902-918 12205444
35. The evolution of cell adhesion. RO Hynes Q Zhao, J Cell Biol 2000 24 F89 F96 10.1083/jcb.150.2.F89
36. Synthesis and biological evaluation of dimeric RGD peptide-Paclitaxel conjugate as a model for integrin-targeted drug delivery. X Chen C Plasencia Y Hou N Neamati, J Med Chem 2005 48 1098 1106 10.1021/jm049165z 15715477
37. RGD modified liposomes targeted to activated platelets as a potential vascular drug delivery system. AS Gupta G Huang BJ Lestini S Sagnella K Kottke-Marchant RE Marchant, Thromb Haemost 2005 93 106 114 15630499
38. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. RM Schiffelers GA Koning TL ten Hagen MH Fens AJ Schraa AP Janssen RJ Kok G Molema G Strom, J Control Rel 2003 91 115 122 10.1016/S0168-3659(03)00240-2
39. Adhesion, migration and communication in melanocytes and melanoma. NK Haass KS Smalley L Li M Herlyn, Pigment Cell Res 2005 18 150 159 10.1111/j.1600-0749.2005.00235.x 15892711
40. Changing neighbours, changing behaviour: Cell adhesion molecule-mediated signalling during tumour progression. G Christofori, EMBO J 2003 22 2318 2323 12743026 10.1093/emboj/cdg228
41. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke: Scientific rationale and available evidence. AM Pancioli TG Brott, CNS Drugs 2004 18 981 988 10.2165/00023210- 200418140-00003 15584768
42. Platelet physiology and thrombosis. RK Andrews MC Berndt, Thromb Res 2004 114 447 453 10.1016/j.thromres.2004.07.020 15507277
43. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: Designing peptide and small molecule inhibitors. ME Anderson TJ Siahaan, Peptides 2003 24 487 501 10.1016/S0196-9781(03)00083-4 12732350
44. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. H Yusuf-Makagiansar ME Anderson TV Yakovleva JS Murray TJ Siahaan, Med Res Rev 2002 22 146 167 10.1002/med.10001 11857637
45. Therapeutic antagonists and the conformational regulation of the 2 integrins. M Shimaoka TA Springer, Curr Top Med Chem 2004 4 1485 1495 10.2174/1568026043387575 15544539
46. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. W Arap RR Pasqualini E Ruoslahti, Science 1998 279 377 380 10.1126/science.279.5349.377 9430587
47. A death-promoting role for extracellular signal-regulated kinase. S Zhuang RG Schnellmann, J Pharmacol Exp Ther 2006 319 991 997 10.1124/jpet.106.107367 16801453
48. Cell adhesion molecules for targeted drug delivery. AL Dunehoo M Anderson S Majumdar N Kobayashi C Berkland TJ Siahaan, J pharmaceutical Sci 2006 95 1856 1872 10.1002/jps.20676
49. Synthesis of PLGA Nanoparticles with Conjugated CLABL as Targeted Vascular Delivery Vehicles. N Zhang C Berkland, Science Talks, Higuchi Biosciences Center, University of Kansas, Lawrence 2006